Inclusion Criteria:  Written informed consent must be obtained before any study-specific assessment is performed Body mass index within the range of 18-35 kg/m2 Patients with a genetic diagnosis of FCAS Patients with a clinical history and investigations consistent with FCAS  Exclusion Criteria:  Participants currently being treated with anti-rejection and/or immunomodulatory drugs and the treatment cannot be discontinued or switched to a different medication Clinically significant, suspected active or chronic bacterial (including Mycobacterium tuberculosis), viral or fungal infection within 30 days prior to dosing. Patients with innate (e.g. TLR immunodeficiencies, defects in IFN-γ signaling) or acquired immune deficiencies (e.g. AIDS). Presence of human immunodeficiency virus (HIV) infection, hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc), or hepatitis C antibodies at screening Live vaccines within 4 weeks of dosing Pregnant or nursing (lactating) women Women of child-bearing potential unless they are using highly effective methods of contraception  Other protocol-defined inclusion/exclusion criteria may apply